ASCO GI 2023 | Monitoring ctDNA in rectal cancer to assess treatment response

Paul Bernard Romesser, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the role of tumor informed circulating tumor DNA (ctDNA) in evaluating progress in patients with rectal cancer. In a cohort of patients receiving chemoradiation, a majority had detectable ctDNA levels at baseline, and half of patients had no detectable ctDNA midway through treatment. Clearance of ctDNA is subsequently correlated with clinical response. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.